269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群 Disease details / Clinical trials / Drug dev / DR info

Adalimumab
   AbbVie
      2017   Phase 3   NCT03311464   Japan
   Wake Forest University Health Sciences
      2007   Phase 2   NCT00690846   United States
ANTI-(complement C5A) IGG4 chimeric monoclonal antibody
   InflaRx GmbH
      2020   Phase 2   EUCTR2020-003273-21-PL   Poland;United States
APD334
   Arena Pharmaceuticals
      2017   Phase 2   NCT03072953   Australia;New Zealand
Baricitinib
   Oregon Health and Science University
      2023   Phase 2   NCT04901325   United States
Canakinumab
   IRCCS ISTITUTO GIANNINA GASLINI
      2023   Phase 3   EUCTR2021-005754-28-IT   Italy
   University of Zurich
      2011   Phase 2   NCT01302795   Switzerland
Ciclosporin
   Nottingham University Hospitals NHS Trust
      2010   -   EUCTR2008-008291-14-IE   Ireland;United Kingdom
      2009   Phase 4   EUCTR2008-008291-14-GB   Ireland;United Kingdom
Cosentyx
   Technische Universität München, School of Medicine, represented by Dean
      2015   Phase 2;Phase 3   EUCTR2015-000762-65-DE   Germany
Dehydrated human amnion/chorion membrane
   Louisiana State University Health Sciences Center in New Orleans
      2021   Phase 4   NCT05120726   United States
Deucravacitinib
   Dartmouth-Hitchcock Medical Center
      2025   Early Phase 1   NCT05821374   United States
EU/1/14/980/002
   Technische Universität München, School of Medicine, represented by Dean
      2015   Phase 2;Phase 3   EUCTR2015-000762-65-DE   Germany
EU/1/14/980/003
   Technische Universität München, School of Medicine, represented by Dean
      2015   Phase 2;Phase 3   EUCTR2015-000762-65-DE   Germany
Gevokizumab
   MedDerm Associates
      2015   Phase 3   NCT02366260   United States
   XOMA (US) LLC
      2014   Phase 3   NCT02318914   Australia;Canada;United States
      2013   Phase 2   NCT01882504   United States
Gevokizumab OPEN-label
   XOMA (US) LLC
      2014   Phase 3   NCT02326740   Australia;Canada;United States
      2014   Phase 3   NCT02315417   United States
Guselkumab
   Oregon Health and Science University
      2025   Phase 2   NCT06563323   United States
Humira
   Wright State University
      2009   Phase 2   NCT00730717   United States
Hyperbaric oxygen
   Erasmus Medical Center
      2022   Phase 3   NCT05343754   Netherlands
IFX-1
   InflaRx GmbH
      2020   Phase 2   EUCTR2020-003273-21-PL   Poland;United States
Infliximab
   University Hospitals Cleveland Medical Center
      2008   -   NCT00791557   United States
Ixekizumab
   Ohio State University
      2017   Phase 2   NCT03137160   United States
Monoclonal antibody (MAB) SB24M
   SWISS BIOPHARMA MED GmbH
      2021   Early Phase 1   NCT04895566   Belarus;Latvia
Neoral oral solution
   Nottingham University Hospitals NHS Trust
      2010   -   EUCTR2008-008291-14-IE   Ireland;United Kingdom
      2009   Phase 4   EUCTR2008-008291-14-GB   Ireland;United Kingdom
Neoral soft gelatin capsules
   Nottingham University Hospitals NHS Trust
      2010   -   EUCTR2008-008291-14-IE   Ireland;United Kingdom
      2009   Phase 4   EUCTR2008-008291-14-GB   Ireland;United Kingdom
Platelet rich plasma therapy
   Ohio State University
      2024   -   NCT05984654   United States
Prednisolone
   Boehringer Ingelheim
      2025   Phase 3   NCT06624670   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Finland;France;Germany;Hungary;Italy;Japan;Malaysia;Norway;Poland;Portugal;Puerto Rico;Spain;Sweden;Switzerland;United States
   Nottingham University Hospitals NHS Trust
      2010   -   EUCTR2008-008291-14-IE   Ireland;United Kingdom
      2009   Phase 4   EUCTR2008-008291-14-GB   Ireland;United Kingdom
Prednisone
   Boehringer Ingelheim
      2025   Phase 3   NCT06624670   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Finland;France;Germany;Hungary;Italy;Japan;Malaysia;Norway;Poland;Portugal;Puerto Rico;Spain;Sweden;Switzerland;United States
Secukinumab
   Technical University of Munich
      2016   Phase 1/Phase 2   NCT02733094   Germany
Secukinumab 150 MG (2 injections PER dose
   Wake Forest University Health Sciences
      2021   Phase 2   NCT04274166   United States
Spesolimab
   Boehringer Ingelheim
      2025   Phase 3   NCT06624670   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Finland;France;Germany;Hungary;Italy;Japan;Malaysia;Norway;Poland;Portugal;Puerto Rico;Spain;Sweden;Switzerland;United States
   Icahn School of Medicine at Mount Sinai
      2023   Phase 2   NCT06092216   United States
Stelara
   University Hospital Tübingen
      2012   Phase 2   EUCTR2011-002920-41-DE   Germany
Ustekinumab
   University Hospital Tübingen
      2012   Phase 2   EUCTR2011-002920-41-DE   Germany
Vilobelimab
   InflaRx GmbH
      2023   Phase 3   NCT05964413   Australia;Belgium;France;Germany;Hungary;Italy;Poland;Spain;Switzerland;United States
      2019   Phase 2   NCT03971643   Canada;Poland;United States
Xilonix
   Janssen Research & Development, LLC
      2014   Phase 2   NCT01965613   United States